See more : Vistal Gdynia S.A. (VTL.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Sienna Biopharmaceuticals, Inc. (SNNAQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sienna Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bougainville Copper Limited (BOC.AX) Income Statement Analysis – Financial Results
- Elysee Development Corp. (ELC.V) Income Statement Analysis – Financial Results
- Ricardo plc (RCDO.L) Income Statement Analysis – Financial Results
- The Food Revolution Group Limited (FOD.AX) Income Statement Analysis – Financial Results
- Orbit Garant Drilling Inc. (OGD.TO) Income Statement Analysis – Financial Results
Sienna Biopharmaceuticals, Inc. (SNNAQ)
About Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 157.00K | 120.00K | 67.00K | 32.00K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -157.00K | -120.00K | -67.00K | -32.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 51.59M | 30.48M | 10.99M | 2.41M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 24.91M | 18.09M | 9.70M | 8.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 24.91M | 18.09M | 9.70M | 8.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 3.03M | -2.26M | 95.00K | -184.00K |
| Operating Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 76.50M | 48.57M | 20.69M | 11.11M |
| Cost & Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 76.50M | 48.57M | 20.69M | 11.11M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 568.00K | 547.00K |
| Depreciation & Amortization | 228.49K | 236.56K | 206.30K | 171.86K | 157.00K | 120.00K | 67.00K | 32.00K |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -76.34M | -48.45M | -20.62M | -11.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | -76.50M | -48.57M | -20.69M | -11.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 3.03M | -2.26M | -473.00K | -184.00K |
| Income Before Tax | 0.00 | 0.00 | 0.00 | 0.00 | -73.47M | -50.84M | -21.16M | -11.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | -157.00K | -290.00K | 663.00K | 0.00 |
| Net Income | 0.00 | 0.00 | 0.00 | 0.00 | -73.31M | -50.55M | -21.83M | -11.29M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -3.59 | -5.19 | -11.23 | -5.81 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -3.59 | -5.19 | -11.23 | -5.81 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 0.00 | 0.00 | 20.45M | 9.74M | 1.94M | 1.94M |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 0.00 | 0.00 | 20.45M | 9.74M | 1.94M | 1.94M |
Source: https://incomestatements.info
Category: Stock Reports